Quilalong, Vance Tyrell P.

HRN: 25-78-26  Sex: Male

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
09/01/2024
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
09/01/2024
09/08/2024
IV
250mg
Q24
Pcap C
Waiting Final Action 

Indication:  Empiric    Type of Infection:  Pneumonia    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: